A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Latest Information Update: 28 Oct 2024
At a glance
- Drugs JNJ 90189892 (Primary)
- Indications Acute-Megakaryocytic-Leukemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 28 Oct 2024 New trial record